<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03501550</url>
  </required_header>
  <id_info>
    <org_study_id>CDI-31244-P2-001</org_study_id>
    <nct_id>NCT03501550</nct_id>
  </id_info>
  <brief_title>Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)</brief_title>
  <official_title>An Open-Label Phase 2a Study Evaluating the Safety and Efficacy of Combination Treatment With 2 Weeks of the Non-Nucleoside Inhibitor CDI 31244 Plus 6 Weeks of Sofosbuvir/Velpatasvir in Subjects With Chronic Hepatitis C Genotype 1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cocrystal Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cocrystal Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label phase 2a study of two week treatment with CDI-31244 and sofosbuvir and veltapasvir
      followed by four week treatment of sofosbuvir and velpatasvir in individuals with chronic
      hepatitis C (HCV) genotype 1 (GT1) infection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is open label and has one treatment group. Eligible HCV GT1 subjects will self
      administer orally 400 mg of CDI-31244 and fixed dose combination of sofosbuvir and
      velpatasvir for 14 days. After 14 days the subjects will continue the treatment for another 4
      weeks on the fixed dose combination sofosbuvir and velpatasvir. The subjects will be followed
      up until 24 weeks after the last dose of sofosbuvir and velpatasvir to determine if sustained
      virologic response at 12 (SVR12) and 24 (SVR24) weeks after treatment have been achieved.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events</measure>
    <time_frame>Day 1 to Day 72</time_frame>
    <description>The safety and the tolerability of CDI-31244 in combination with SOF/VEL through number of AEs observed in participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with sustained virologic response (SVR) 12 weeks after discontinuation of therapy (SVR12)</measure>
    <time_frame>post-treatment Week 12</time_frame>
    <description>SVR12 is defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) at 12 weeks after stopping study treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of participants with sustained virologic response (SVR) 24 weeks after discontinuation of therapy (SVR24)</measure>
    <time_frame>post-treatment Week 24</time_frame>
    <description>SVR24 is defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) at 24 weeks after stopping study treatment.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Chronic Hepatitis c</condition>
  <arm_group>
    <arm_group_label>CDI-31244 + SOF/VEL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDI-31244 in combination with SOF/VEL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDI-31244</intervention_name>
    <description>investigational drug</description>
    <arm_group_label>CDI-31244 + SOF/VEL</arm_group_label>
    <other_name>CDI-31244 (non-nucleoside inhibitor or NNI)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF/VEL</intervention_name>
    <description>sofosbuvir and velpatasvir fixed dose combination</description>
    <arm_group_label>CDI-31244 + SOF/VEL</arm_group_label>
    <other_name>Epclusa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        Documented chronic HCV GT 1 infection; Serum HCV RNA &gt;1,000 IU/mL during screening; Absence
        of advanced fibrosis or cirrhosis

        Key Exclusion Criteria:

        Nursing or pregnant women; Active hepatitis B infection; Human immunodeficiency virus (HIV)
        infection; History of use of any HCV direct-acting antiviral therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Chua, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Human Virology, University of Maryland, Baltimore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Luz Pascual, MD</last_name>
    <phone>6788928808</phone>
    <email>lpascual@cocrystalpharma.com</email>
  </overall_contact>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2018</study_first_submitted>
  <study_first_submitted_qc>April 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>GT1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

